Why the study?
What is the incidence and clinical impact of worsening renal function after TAVR in patients with underlying CKD?
What is the incidence and clinical impact of worsening renal function after TAVR in patients with underlying CKD?
Worsening renal function occurs in about 15% of CKD patients 3-6 months post-TAVR and is linked to long-term mortality, emphasizing the need to prevent AKI and major bleeding.
Answers are grounded in this paper and cite their sources.
Post-TAVR renal monitoring in CKD patients may flag mortality risk; leaves open whether targeting AKI or transfusions alters outcomes.
Key Points A significant proportion of patients undergoing transcatheter aortic valve replacement (TAVR) has underlying chronic kidney disease (CKD). Approximately 15% of patients with CKD develop worsening renal function at 3–6 months after TAVR. Worsening renal function at 3–6 months is independently associated with long‐term mortality. Acute kidney injury (AKI) and peri‐procedural blood transfusion of ≥4 units are independently associated with worsening renal function at 3–6 months. Incorporating strategies to mitigate the hazards of AKI and major bleeding in this high‐risk cohort is imperative.
No takes yet. Share an insight, caveat, or question.
Elgendy et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: